Azitra, Inc. (NYSE American: AZTR) announced that Cofounder and Chief Operating Officer Travis Whitfill, Ph.D., MPH, will present data regarding its ATR-COSF program at the BIO-Europe conference in Cologne, Germany, on November 10, 2026, at 4:45 pm CET.
The presentation will cover results from an ex vivo human torso skin model. According to the company, a single application of ATR-COSF, a recombinant filaggrin protein, elicited a 56% reduction in wrinkles from baseline. Additionally, the formulation was shown to improve elasticity and reduce the depth of wrinkles compared to a vehicle control in ex vivo models after 48 hours.
Dr. Whitfill will also provide updates on the company’s ATR-04 program. The Phase 1/2 trial of ATR-04 is ongoing and was expanded in October 2026 to include patients with rashes caused by KRAS and MEK inhibitors, in addition to those caused by EGFR inhibitors, as well as patients with neurofibromatosis type 1 (NF1) experiencing rash from MEK inhibitors. Azitra estimates that approximately 85,000 patients undergo KRAS or MEK inhibitor treatment in the United States annually, alongside about 220,000 patients undergoing EGFR inhibitor treatment.
The company noted that it has received Fast Track designation from the FDA for cancer treatment-associated rash, which impacts up to 300,000 people in the U.S. Azitra aims to begin a first-in-human study for ATR-COSF, with initial results anticipated by year-end.
